Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel and Carboplatin in Recurrent Ovarian Cancer
NCT02026921Phase 2Completed
- Sponsor
- Nordic Society of Gynaecological Oncology Clinical Trial Unit
- Start
- Jun 2004
- Primary completion
- Mar 2006
- Modality
- DNA Intercalators/Alkylators
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of carboplatin and docetaxel in ovarian epithelial cancer, fallopian tube cancer (PFTC) and primary peritoneal carcinoma (PPC), sponsored by Nordic Society of Gynaecological Oncology Clinical Trial Unit. Primary endpoint: Safety at 30 days. Started Jun 2004; status: completed.
02
Drugs
carboplatindocetaxel
03
Conditions
ovarian epithelial cancerfallopian tube cancer (PFTC)primary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT02026921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02026921.